Welcome to our dedicated page for Nexgel Wt Exp 120126 news (Ticker: NXGLW), a resource for investors and traders seeking the latest updates and insights on Nexgel Wt Exp 120126 stock.
NEXGEL, Inc. (NASDAQ: NXGL, warrants: NXGLW) regularly issues news and regulatory updates that highlight its activities in healthcare, beauty and over-the-counter (OTC) hydrogel products, contract manufacturing, and drug delivery initiatives. This news page aggregates those announcements so readers can review how the company describes its progress, partnerships and financial results over time.
Recent press releases have focused on quarterly financial results, where NEXGEL reports revenue, gross profit, operating expenses, net loss and non-GAAP measures such as EBITDA and Adjusted EBITDA. Management commentary in these releases discusses performance in contract manufacturing and consumer branded products, including references to partnerships with organizations like Cintas and STADA, and to consumer demand for brands such as Silly George within the company’s broader portfolio.
NEXGEL’s news flow also includes strategic and corporate developments. The company announced the spin-off of select drug delivery application assets into NexGelRx, an entity that will focus on prescription (Rx) drug delivery solutions using NEXGEL’s proprietary hydrogel technology. Follow-up news detailed strategic investments into NexGelRx from investors associated with Diesis Holdings, LLC and the appointment of a board observer and advisor with experience in reimbursement strategy and healthcare commercialization.
Other announcements cover capital markets transactions, such as registered direct offerings and concurrent private placements of common stock and warrants, as well as expanded partnerships like the agreement with STADA Arzneimittel AG, which includes non-dilutive capital to support product launches and marketing efforts in North America. NEXGEL also issues notices about upcoming earnings calls, conference presentations, and new investor presentations furnished via Form 8-K.
Investors and observers can use this news feed to follow NEXGEL’s own descriptions of its financial performance, hydrogel-based product initiatives, partnership activity and governance decisions, and to track how the company communicates its strategy and operations over time.
NEXGEL has partnered with STADA Arzneimittel AG to launch Histasolv, a leading Diamine Oxidase (DAO) enzyme supplement, in North America. Histasolv, known as DAOSIN in Europe, generates over $10 million annually in Europe, treating histamine food intolerance. NEXGEL will start direct-to-consumer sales in Q3 2024. The product's unique formulation ensures high potency, addressing migraines, gut issues, and skin conditions caused by histamine intolerance. STADA, a top European healthcare company, aims to strengthen its North American presence through this partnership. Both companies express confidence in the collaborative potential and future expansion opportunities.
NEXGEL (NASDAQ: NXGL) has acquired Silly George, an international beauty brand specializing in eye and eyelash products, for $400,000 in cash, $200,000 in NEXGEL common stock, and a 4-year net profit earn out. Silly George, with a revenue run rate of approximately $2 million, offers a range of products including non-toxic eyelash extensions and lash serums, predominantly sold direct-to-consumer and on Amazon in the U.S., U.K., Australia, and the Netherlands. The acquisition is expected to add $2 million in annual revenue and provides operational synergies through marketing optimization and expense overlap. Silly George's strong social media presence and customer database will also offer cross-selling opportunities for NEXGEL's portfolio. CEO Adam Levy highlighted the acquisition as a strategic move towards profitability, leveraging synergies and expanding their product portfolio in the health and beauty sector.
NEXGEL (NASDAQ: NXGL) announced its financial results for Q1 2024, reporting a 104% YoY revenue increase to $1.27 million, driven by 58% growth in contract manufacturing and 178% in consumer branded products. The gross profit for Q1 2024 was $277,000, up from a loss of $57,000 in Q1 2023. However, the company reported a net loss of $905,000, up from $807,000 in the same period last year. NEXGEL is investing in significant growth opportunities, including expanding its Texas facility and launching products in Europe. The company ended the quarter with a cash balance of $2.4 million.
NEXGEL, Inc. will report its first quarter 2024 financial results on May 13th, followed by a conference call at 4:30 P.M. ET. The company is a leading provider of medical and over-the-counter products, including hydrogels for healthcare and consumer applications.
NEXGEL, Inc. will be presenting at the Aegis Capital Virtual Conference on May 9, 2024. The company specializes in medical and OTC products, such as hydrogels, for healthcare and consumer use. The CEO, Adam Levy, will be the speaker at the conference.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.